# Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.

> **NCT05532072** · EARLY_PHASE1 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 140 (estimated)

## Conditions studied

- Graves Ophthalmopathy

## Interventions

- **DRUG:** Rapamycin
- **DRUG:** Methylprednisolone

## Key facts

- **NCT ID:** NCT05532072
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09
- **Primary completion:** 2023-09
- **Final completion:** 2023-09
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2022-09-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05532072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05532072, "Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05532072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*